EDIT
Editas Medicine Inc
2.70$
-7.9%
vs. previous close
Closing price · As of: Sep 23, 2026
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +5,133.3% | +200.0% | +155.2% | +123.2% | +21.3% | -13.0% | +39.9% | +27.6% | +25.4% | -4.3% | -4.2% | -9.2% | |
| – | -8.3% | +6,287.3% | +380.5% | +38.4% | +13.8% | +2.4% | -15.0% | +87.4% | -32.5% | -32.4% | +8.2% | -53.3% | |
| – | – | +2,023.7% | -32.1% | +34.9% | +0.6% | -35.6% | +108.8% | -11.2% | -36.6% | – | – | – | |
| – | +251.6% | +1,450.6% | -70.6% | +281.4% | -61.9% | +145.2% | -255.0% | – | – | -119.5% | – | -1,005.2% | |
| – | +665.4% | +17.6% | +144.1% | -41.1% | +130.9% | +29.7% | +16.1% | +11.4% | -48.4% | +14.6% | +87.0% | -93.1% | |
| – | +665.4% | +17.6% | +255.8% | +3,509.8% | -71.1% | – | -1,246.9% | -61.2% | – | -103.3% | – | -14.5% | |
| – | – | – | -99.5% | -98.6% | -63.6% | – | – | – | – | – | – | – | |
| – | – | -58.5% | -35.3% | +0.0% | -63.6% | +3,295,500.0% | +70.0% | +25.9% | -99.5% | – | – | – | |
| – | – | -208.2% | +12.0% | +143.6% | -37.2% | – | – | – | – | – | – | – | |
| – | +105.8% | +654.2% | -30.3% | +59.0% | -43.7% | +51.6% | +70.0% | +25.9% | -99.5% | +9,093.1% | -52.5% | -27.8% | |
| – | +42.7% | +1,439.4% | -68.2% | -191.8% | – | – | -193.1% | – | -197.1% | – | – | +76.2% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – |
Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.